Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) EBIT per Share : $-6.12 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings EBIT per Share?

Sonnet BioTherapeutics Holdings's EBIT per Share for the three months ended in Mar. 2024 was $-0.79. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.12.

During the past 3 years, the average EBIT per Share Growth Rate was 68.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's EBIT per Share or its related term are showing as below:

SONN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 18.4 Med: 43.3 Max: 68.2
Current: 68.2

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Sonnet BioTherapeutics Holdings was 68.20% per year. The lowest was 18.40% per year. And the median was 43.30% per year.

SONN's 3-Year EBIT Growth Rate is ranked better than
97.39% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs SONN: 68.20

Sonnet BioTherapeutics Holdings's EBIT for the three months ended in Mar. 2024 was $-3.87 Mil.

Sonnet BioTherapeutics Holdings EBIT per Share Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings EBIT per Share Chart

Sonnet BioTherapeutics Holdings Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT per Share

-276.94

-561.65

-313.59

-150.60

-18.11

Sonnet BioTherapeutics Holdings Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial													-7.54	-2.93	-2.06	-0.34	-0.79

Sonnet BioTherapeutics Holdings EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Sonnet BioTherapeutics Holdings's EBIT per Share for the fiscal year that ended in Sep. 2023 is calculated as

	EBIT per Share		(A: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-18.793	/	1.038
=	-18.11

Sonnet BioTherapeutics Holdings's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.869	/	4.886
=	-0.79

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.12

Sonnet BioTherapeutics Holdings (NAS:SONN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Sonnet BioTherapeutics Holdings EBIT per Share Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings (Sonnet BioTherapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540

Website

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Executives

John Markey	10 percent owner	10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter	officer: Chief Technical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan	director, officer: Chairman, President and CEO	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney	officer: Chief Medical Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg	officer: Chief Medical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini	officer: Chief Scientific Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii	officer: Chief Financial Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc	10 percent owner	918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701